Phase 1 study of sorafenib and eribulin in patients with advanced, metastatic or refractory solid tumors
© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Background: Combining sorafenib (SOR), an oral multikinase inhibitor approved for hepatocellular carcinoma,...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
1 October 2016
|
| In: |
Annals of oncology
Year: 2016, Volume: 27, Pages: vi114-vi135 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdw368.40 |
| Online Access: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1093/annonc/mdw368.40 Verlag, kostenfrei, Volltext: https://academic.oup.com/annonc/article/27/suppl_6/397P/2799135/Phase-1-study-of-sorafenib-and-eribulin-in 
|
| Author Notes: | F. Marmé, C. Gomez-Roca, K. Graudenz, F. Huang, J. Lettieri, C. Pena, Z. Trnkova, J. Eucker |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1562795910 | ||
| 003 | DE-627 | ||
| 005 | 20230427122042.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 170828s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/annonc/mdw368.40 |2 doi | |
| 035 | |a (DE-627)1562795910 | ||
| 035 | |a (DE-576)492795916 | ||
| 035 | |a (DE-599)BSZ492795916 | ||
| 035 | |a (OCoLC)1340978850 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Marmé, Frederik |d 1974- |e VerfasserIn |0 (DE-588)132561972 |0 (DE-627)52394893X |0 (DE-576)299226549 |4 aut | |
| 245 | 1 | 0 | |a Phase 1 study of sorafenib and eribulin in patients with advanced, metastatic or refractory solid tumors |c F. Marmé, C. Gomez-Roca, K. Graudenz, F. Huang, J. Lettieri, C. Pena, Z. Trnkova, J. Eucker |
| 264 | 1 | |c 1 October 2016 | |
| 300 | |a 22 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 28.08.2017 | ||
| 520 | |a © The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.com.Background: Combining sorafenib (SOR), an oral multikinase inhibitor approved for hepatocellular carcinoma, renal cell carcinoma, and differentiated thyroid carcinoma, with eribulin mesylate (ERI), a microtubule inhibitor approved for breast cancer (BC), may provide synergistic antitumor activities.Methods: This phase 1b, open label, dose escalation study evaluated safety, pharmacokinetics (PK), maximum tolerated dose/recommended phase 2 dose (MTD/RP2D), cardiac safety (QT/QTc), and preliminary efficacy of SOR + standard dose ERI (1.4 mg/kg IV on Days [D] 1 and 8 of each 21-day cycle [C]) in patients (pts) with advanced, metastatic, or refractory tumors. Starting SOR dose was 200 mg BID continuously starting on D11 of C1. SOR + ERI-related hematologic and nonhematologic dose limiting toxicities (DLT) were assessed in C2. If tolerable, SOR was escalated in... | ||
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 27(2016), Supplement 6, Seite vi114-vi135 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a Phase 1 study of sorafenib and eribulin in patients with advanced, metastatic or refractory solid tumors |
| 773 | 1 | 8 | |g volume:27 |g year:2016 |g supplement:Supplement 6 |g pages:vi114-vi135 |g extent:22 |a Phase 1 study of sorafenib and eribulin in patients with advanced, metastatic or refractory solid tumors |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/annonc/mdw368.40 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://academic.oup.com/annonc/article/27/suppl_6/397P/2799135/Phase-1-study-of-sorafenib-and-eribulin-in |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20170828 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 132561972 |a Marmé, Frederik |m 132561972:Marmé, Frederik |d 910000 |e 910000PM132561972 |k 0/910000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1562795910 |e 2978657006 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 28.08.2017"],"relHost":[{"type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["1.1990 -"],"recId":"320428796","disp":"Phase 1 study of sorafenib and eribulin in patients with advanced, metastatic or refractory solid tumorsAnnals of oncology","language":["eng"],"part":{"volume":"27","text":"27(2016), Supplement 6, Seite vi114-vi135","year":"2016","extent":"22","pages":"vi114-vi135"},"id":{"zdb":["2003498-2"],"issn":["1569-8041"],"eki":["320428796"]},"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"corporate":[{"display":"European Society for Medical Oncology","role":"isb"}],"origin":[{"dateIssuedKey":"1990","publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford","publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","dateIssuedDisp":"1990-"}],"title":[{"title_sort":"Annals of oncology","subtitle":"official journal of the European Society for Medical Oncology","title":"Annals of oncology"}]}],"id":{"doi":["10.1093/annonc/mdw368.40"],"eki":["1562795910"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"physDesc":[{"extent":"22 S."}],"title":[{"title_sort":"Phase 1 study of sorafenib and eribulin in patients with advanced, metastatic or refractory solid tumors","title":"Phase 1 study of sorafenib and eribulin in patients with advanced, metastatic or refractory solid tumors"}],"language":["eng"],"origin":[{"dateIssuedDisp":"1 October 2016","dateIssuedKey":"2016"}],"name":{"displayForm":["F. Marmé, C. Gomez-Roca, K. Graudenz, F. Huang, J. Lettieri, C. Pena, Z. Trnkova, J. Eucker"]},"recId":"1562795910","person":[{"role":"aut","display":"Marmé, Frederik","given":"Frederik","family":"Marmé"}]} | ||
| SRT | |a MARMEFREDEPHASE1STUD1201 | ||